|
|
Article: CoTherix Licenses Fasudil For PAH From Asahi Kasei.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Building its bid for a larger share of the pulmonary arterial hypertension market, CoTherix Inc. licensed rights in North America and Europe from Asahi Kasei Pharma Corp. to develop and commercialize oral and inhaled fasudil, a rho-kinase inhibitor for PAH.
CoTherix, which also acquired exclusive rights to fasudil for stable angina in the same territories, will provide an up-front payment of $8.75 million to Tokyo-based Asahi, plus milestone payments and royalties on future products. The deal carries an option for CoTherix to develop fasudil in North America and Europe for other potential indications using the licensed formulations, ...